Xilio Therapeutics Inc (XLO) concluded trading on Thursday at a closing price of $0.94, with 3.72 million shares of worth about $3.5 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 3.26% during that period and on December 19, 2024 the price saw a gain of about 8.25%. Currently the company’s common shares owned by public are about 43.96M shares, out of which, 20.53M shares are available for trading.
Stock saw a price change of -8.93% in past 5 days and over the past one month there was a price change of -8.04%. Year-to-date (YTD), XLO shares are showing a performance of 70.55% which increased to 56.07% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.49 but also hit the highest price of $1.93 during that period. The average intraday trading volume for Xilio Therapeutics Inc shares is 237.58K. The stock is currently trading -5.75% below its 20-day simple moving average (SMA20), while that difference is down -6.38% for SMA50 and it goes to -3.13% lower than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Xilio Therapeutics Inc (NASDAQ: XLO) currently have 43.96M outstanding shares and institutions hold larger chunk of about 16.09% of that.
The stock has a current market capitalization of $41.23M and its 3Y-monthly beta is at -0.19. It has posted earnings per share of -$1.72 in the same period. It has Quick Ratio of 1.67 while making debt-to-equity ratio of 0.40. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for XLO, volatility over the week remained 13.62% while standing at 10.10% over the month.
Stock’s fiscal year EPS is expected to rise by 58.99% while it is estimated to increase by 55.56% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Chardan Capital Markets on December 21, 2022 offering a Buy rating for the stock and assigned a target price of $7 to it. Coverage by H.C. Wainwright stated Xilio Therapeutics Inc (XLO) stock as a Buy in their note to investors on January 10, 2022, suggesting a price target of $36 for the stock. On November 16, 2021, Raymond James Initiated their recommendations, while on November 16, 2021, Morgan Stanley Initiated their ratings for the stock with a price target of $32. Stock get a Buy rating from Guggenheim on November 16, 2021.
